Shares of Ipca Laboratories declined by 2.07%, trading at Rs 1,370.30 on Tuesday. The stock is a constituent of the Nifty Midcap 150 index.
Financial Performance:
Ipca Laboratories has demonstrated consistent financial performance. The consolidated revenue for the quarter-ending June 2025 stood at Rs 2,308.85 Crore, compared to Rs 2,092.63 Crore in June 2024. The net profit for the same period was Rs 234.42 Crore, up from Rs 198.98 Crore in the previous year.
Quarterly Financials:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,092.63 Crore | Rs 2,354.90 Crore | Rs 2,245.37 Crore | Rs 2,246.69 Crore | Rs 2,308.85 Crore |
| Net Profit | Rs 198.98 Crore | Rs 245.44 Crore | Rs 277.33 Crore | Rs 65.78 Crore | Rs 234.42 Crore |
| EPS | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 |
The consolidated revenue for the year-ending March 2025 was Rs 8,939.59 Crore, a notable increase from Rs 7,705.04 Crore in the previous year. Net profit for the year-ending March 2025 stood at Rs 787.53 Crore compared to Rs 529.21 Crore in March 2024. Earnings per share (EPS) increased to Rs 35.14 in March 2025 from Rs 25.82 in March 2024.
Yearly Financials:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 5,419.99 Crore | Rs 5,829.79 Crore | Rs 6,244.32 Crore | Rs 7,705.04 Crore | Rs 8,939.59 Crore |
| Net Profit | Rs 1,148.84 Crore | Rs 910.95 Crore | Rs 491.93 Crore | Rs 529.21 Crore | Rs 787.53 Crore |
| EPS | 45.01 | 34.85 | 18.58 | 25.82 | 35.14 |
| BVPS | 371.79 | 219.51 | 233.16 | 304.57 | 273.88 |
| ROE | 24.24 | 16.09 | 8.06 | 8.64 | 10.61 |
| Debt to Equity | 0.05 | 0.14 | 0.25 | 0.22 | 0.19 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 8,939 Crore | Rs 7,705 Crore | Rs 6,244 Crore | Rs 5,829 Crore | Rs 5,419 Crore |
| Other Income | Rs 92 Crore | Rs 124 Crore | Rs 125 Crore | Rs 66 Crore | Rs 62 Crore |
| Total Income | Rs 9,032 Crore | Rs 7,829 Crore | Rs 6,369 Crore | Rs 5,896 Crore | Rs 5,482 Crore |
| Total Expenditure | Rs 7,816 Crore | Rs 6,848 Crore | Rs 5,579 Crore | Rs 4,752 Crore | Rs 4,084 Crore |
| EBIT | Rs 1,216 Crore | Rs 980 Crore | Rs 790 Crore | Rs 1,143 Crore | Rs 1,398 Crore |
| Interest | Rs 84 Crore | Rs 138 Crore | Rs 45 Crore | Rs 7 Crore | Rs 9 Crore |
| Tax | Rs 343 Crore | Rs 313 Crore | Rs 253 Crore | Rs 224 Crore | Rs 240 Crore |
| Net Profit | Rs 787 Crore | Rs 529 Crore | Rs 491 Crore | Rs 910 Crore | Rs 1,148 Crore |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 1,321 Crore | Rs 944 Crore | Rs 805 Crore | Rs 856 Crore | Rs 1,090 Crore |
| Investing Activities | Rs -869 Crore | Rs -1,291 Crore | Rs -725 Crore | Rs -855 Crore | Rs -520 Crore |
| Financing Activities | Rs -282 Crore | Rs -552 Crore | Rs 507 Crore | Rs 426 Crore | Rs -305 Crore |
| Others | Rs 0 Crore | Rs 76 Crore | Rs 0 Crore | Rs 4 Crore | Rs 0 Crore |
| Net Cash Flow | Rs 168 Crore | Rs -823 Crore | Rs 588 Crore | Rs 431 Crore | Rs 263 Crore |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore |
| Reserves & Surplus | Rs 6,923 Crore | Rs 6,306 Crore | Rs 5,816 Crore | Rs 5,466 Crore | Rs 4,676 Crore |
| Current Liabilities | Rs 2,386 Crore | Rs 2,355 Crore | Rs 1,805 Crore | Rs 1,465 Crore | Rs 1,160 Crore |
| Other Liabilities | Rs 2,425 Crore | Rs 2,413 Crore | Rs 978 Crore | Rs 681 Crore | Rs 206 Crore |
| Total Liabilities | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Fixed Assets | Rs 4,798 Crore | Rs 4,805 Crore | Rs 2,853 Crore | Rs 2,669 Crore | Rs 2,260 Crore |
| Current Assets | Rs 6,268 Crore | Rs 5,538 Crore | Rs 5,189 Crore | Rs 4,457 Crore | Rs 3,436 Crore |
| Other Assets | Rs 694 Crore | Rs 756 Crore | Rs 583 Crore | Rs 511 Crore | Rs 370 Crore |
| Total Assets | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Contingent Liabilities | Rs 613 Crore | Rs 303 Crore | Rs 2,125 Crore | Rs 274 Crore | Rs 369 Crore |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 35.14 | 25.82 | 18.58 | 34.85 | 45.01 |
| Diluted Eps (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 45.01 |
| Book Value /Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Dividend/Share (Rs.) | 4.00 | 4.00 | 4.00 | 4.00 | 8.00 |
| Face Value | 1 | 1 | 1 | 1 | 2 |
| Gross Profit Margin (%) | 20.34 | 18.76 | 16.85 | 23.59 | 29.65 |
| Operating Margin (%) | 15.89 | 14.12 | 12.66 | 19.61 | 25.79 |
| Net Profit Margin (%) | 8.80 | 6.86 | 7.87 | 15.62 | 21.19 |
| Return on Networth / Equity (%) | 10.61 | 8.64 | 8.06 | 16.09 | 24.24 |
| ROCE (%) | 15.15 | 12.44 | 11.59 | 18.52 | 28.48 |
| Return On Assets (%) | 6.27 | 4.93 | 5.46 | 11.57 | 18.78 |
| Current Ratio (X) | 2.63 | 2.35 | 2.87 | 3.04 | 2.96 |
| Quick Ratio (X) | 1.55 | 1.30 | 1.91 | 1.77 | 1.59 |
| Debt to Equity (x) | 0.19 | 0.22 | 0.25 | 0.14 | 0.05 |
| Interest Coverage Ratios (X) | 21.42 | 10.46 | 23.11 | 178.91 | 177.79 |
| Asset Turnover Ratio (%) | 0.78 | 0.78 | 0.77 | 0.80 | 0.91 |
| Inventory Turnover Ratio (X) | 3.55 | 1.05 | 0.95 | 0.96 | 1.10 |
| 3 Yr CAGR Sales (%) | 23.83 | 19.23 | 15.90 | 24.30 | 28.99 |
| 3 Yr CAGR Net Profit (%) | -7.02 | -32.13 | -10.30 | 43.23 | 117.14 |
| P/E (x) | 42.74 | 47.92 | 43.61 | 30.58 | 21.15 |
| P/B (x) | 5.48 | 4.96 | 3.52 | 4.90 | 5.13 |
| EV/EBITDA (x) | 22.26 | 23.45 | 19.23 | 19.73 | 14.96 |
| P/S (x) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
Ipca Laboratories announced the closure of the trading window, as per an announcement on September 22, 2025. Other corporate actions include relodgement of transfer requests for physical shares and newspaper publications. The company has announced a final dividend of Rs 2.00 per share (200%) on May 29, 2025, with an effective date of August 05, 2025. It also announced an interim dividend of Rs 2.00 per share (200%) on October 24, 2024, which was revised with an effective date of November 25, 2024. The company had a bonus issue of 1:1, with the ex-bonus date on January 28, 2005. A stock split occurred on January 10, 2022, with the face value changing from Rs 2 to Rs 1.
Moneycontrol analysis, as of September 19, 2025, suggests a very bullish sentiment on the stock.
With the stock's last traded price at Rs 1,370.30, Ipca Laboratories has seen a decline of 2.07% today.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
